Posts Tagged ‘agitation’

Prozac is now a defense for murder, writes Australian Member of Parliament Martin Whitely

Wednesday, December 21st, 2011

For the first time in criminal history, a murder was attributed to an anti-depressant drug. (Photo Credit -The Daily Telegraph)

Perth Now – December 21, 2011

FIRST it was ADHD drugs, then organ donation, now WA Labor MP Martin Whitely is hoping to get some action on the fatal risks of antidepressant drugs, such as Prozac, to children.

Anti-depressant manufacturers warn that products such as Prozac should not be given to children, because of the potentially tragic consequences, but they are prescribed every day to Australian kids.

Some anti-depressants, prescribed to help lift people out of a depressive state, actually have the opposite effect and make things worse.

This is what happened, with fatal results, in the case of a 16-year-old boy in Canada who stabbed a friend to death.

For the first time in criminal history, a murder was attributed to an anti-depressant drug.

In the finding, handed down on the 16th of September 2011, a Canadian Judge said a 16-year-old boy, who stabbed his brother’s friend in the stomach, would not have committed the offence had he not been treated with the drug Prozac (a brand of Fluoxetine).

The judge accepted the evidence of psychiatrist, Dr Peter Breggin, who told the court the boy’s symptoms were consistent with a Prozac-Induced Mood Disorder with Manic Features.

In delivering his decision the judge stated, “his basic normalcy now further confirms he no longer poses a risk of violence to anyone and that his mental deterioration and resulting violence would not have taken place without exposure to Prozac”.

The boy, who had no history of violence, had been taking Prozac for three months, during which his parents observed a marked deterioration in his behaviour and mood, which included acts of violence and self-harm where previously no such signs existed.

His alarmed parents returned to his doctor for advice, but instead of taking him off Prozac or reducing his dosage, his doctor increased the dose, obviously believing more of what appeared to be causing these dangerous behaviours, would solve the problem.

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and is approved for use in Australia for the treatment of depression, obsessive compulsive disorder and premenstrual dysphoric disorder.

However, it is routinely prescribed ‘off label’ for a range of other conditions including panic and eating disorders.

Australian Government Department of Health and Ageing figures revealed that in the 2008 financial year, 110,848 Australians received Fluoxetine scripts that were subsidised via the Pharmaceutical Benefits Scheme.

Concerns about possible aggression and manic side effects of Prozac were first raised in Australia in the New South Wales parliament in 1995, just five years after the release of the drug in Australia.

Since 2007, the US Food and Drug Administration has labelled SSRI antidepressants including Prozac with the highest possible ‘black box’ warning stating:

“All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and non-psychiatric.”

The US Black Box warning was followed by similar warnings in Australia. The evidence that led to these warnings came from, ‘pooled analyses of short-term placebo-controlled trials of anti-depressant drugs (SSRIs and others)’ which ‘showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents [by 100%], and young adults ages 18-24 (by 50 per cent) with major depressive disorder (MDD) and other psychiatric disorders.’ The fact that SSRI antidepressants like Prozac are supposed to manage severe depression in young people but increase the risk of suicidality poses obvious questions.

Over a 10 year period, up until 30 June 2011, more than 40 adverse events of self-harm and violence, including suicides, homicides and suicidal or homicidal ideation, for Fluoxetine were reported to the Australian Therapeutic Drugs Administration (examples are listed below).

Hundreds of reports were recorded by the TGA for other antidepressants however, it is impossible to know the true number of actual events, as the voluntary nature of the reporting system means only a fraction of actual incidents gets reported.

Despite the fact that the manufacturers advise that Prozac and other SSRI antidepressants are ‘not recommended for use in children and adolescents under 18 years of age’ they are frequently prescribed ‘off label’ to even very young children.

Data provided by the Commonwealth Department of Health revealed that in the 2007-8 financial year 3,752 Australian children 15-years-old or younger (863 were 10 or younger, 117 were six or younger) were prescribed Pharmaceutical Benefits Scheme-funded Fluoxetine.

Furthermore all the expense and risks of adverse side effects may be for little or no benefit. The efficacy of antidepressants are being questioned – with some high profile, mainstream critics, arguing that placebos are just as effective and much safer in treating moderate depression.

One such critic, Marcia Angell, MD, Senior Lecturer on Social Medicine at Harvard Medical School and former Editor-in-Chief of The New England Journal of Medicine, contends; ‘that clinical trials have failed to find antidepressants effective at all in mild to moderate depression; that many psychiatric drugs have devastating adverse effects, especially in children and when used long-term; and that despite the risks and uncertain benefits, use of psychiatric drugs is soaring and the heavy reliance on drugs diverts resources better spent on improving treatment’.

In summary, taxpayers are subsidising the ‘off label’ use by children and adolescents of antidepressants, with questionable efficacy, that double their risk of suicidality. This invites some obvious questions: Is this the best way to spend our taxes? And more importantly, is this the best way to help troubled young people?

* A sample from the Adverse Drug Reactions Committee (ADRAC) adverse event reports for Fluoxetine Hydrochloride:

  • A 54 year old woman attempted suicide. She was also suffering from mania and a confusional state.
  • A 36 year old woman “attempted suicide”.
  • A 36 year old woman was admitted to intensive care in a coma following a suicide attempt.
  • A 51 year old woman “had sudden urge to murder someone”.
  • A 37 year old woman was admitted to a psychiatric hospital suffering from “suicidal ideation, nausea, trembling, feelings of despair, anxiety, paranoia and fear”.
  • A 16 year old boy suffering from agitation and auditory hallucinations heard voices “telling him to kill his mother, father, sister and himself”.
  • A 45 year old man “became obsessively suicidal and cut his throat” 3/7 days after Prozac was stopped.
  • A 17 year old girl “became manic half an hour after commencing antidepressant.”
  • A 40 year old patient “experienced trembling, cramps, heard voices and had suicidal ideation.”
  • A patient of unrecorded gender and age experienced “homicidal and suicidal ideation.”
  • A patient of unrecorded gender and age attempted suicide after experiencing suicidal ideation.
  • A 44 year old patient “experienced akathisia, suicidal ideation and suicide attempt.”
  • A patient of unrecorded gender and age experienced “suicidal violence” and “aggression.”
  • A patient of unrecorded gender and age experienced “suicidal ideation.”
  • A patient of unrecorded gender and age experienced “suicidal ideation and “suicide attempt.”
  • A 50 year old patient experienced “suicidal ideation, suicide attempt and akathisia.”
  • A 37 year old patient attempted suicide.
  • A patient of unrecorded gender and age experienced “suicidal ideation and suicide attempt.”
  • A patient of unrecorded gender and age made a suicide attempt and was violent.
  • A 16 year old girl “attempted to hang herself with television cord from curtain rail in hospital bedroom. Nurse said she found her at the last moment.”
  • A 16year old girl “ingested 40 Panadol tablets. Also frequent self-harming.”
  • A 16 year old girl “attempted suicide by ingestion of 80 Panadol, 20 Panadeine, 7 Olanzapine.”
  • A 29 year old patient “developed acute suicidal akathisia” and made a suicide attempt.
  • A 73 year old patient “experienced homicidal ideation and made a suicide attempt.”
  • A 60 year old woman “experienced suicidal ideation, suicide attempt and homicidal ideation – she attempted to kill her parents.”
  • A 69 year old patient “experienced suicidal ideation and was very anxious.”
  • A 16 year old girl attempted to “strangle herself with and IPod cord in the bathroom of the hospital. Agitation. She ran around crying and banging her fists of the walls and windows begging to be let out. … it lasted about 10 minutes before I could settle her.”
  • A patient of unrecorded gender and age “took a fistful of sleeping pills.”
  • A 35 year old patient “murdered his wife whilst on Prozac. He had also experienced suicidal thoughts.”
  • A female patient of unrecorded age “became seriously depressed, complained of headaches, and clenching jaw, was unable to sleep and started to self-harm. She began to have suicidal thoughts, was hyperventilating, agoraphobic, had five suicide attempts, was confused, tearful, phobic, aggressive, experienced akathisia and suspected serotonin syndrome. She experienced weird dreams, was impulsive, light headed, had numbness and tingling limbs and committed suicide by hanging on 11 September 2000 on the second attempt.”
  • A 50 year old woman “became more depressed whilst taking Prozac. She wanted to throw herself off a train or bus, had difficulty sleeping, was pacing and restless, had voice hallucinations, would look in the mirror and see a different person, had murderous thoughts, stiff legs, was hot a lot, felt she was in a delirium, could not concentrate, was angry, had numbness in her hands and pins and needles a lot in her body.”
  • A 19 year old male “had thoughts about killing himself which made him violent, tried to hit someone else, tried to hit a security guard with feelings of killing and tried to do physical damage. Tried to hurt himself and had thoughts of hurting other people. He was walking faster than normal. Experienced aggression, insomnia and was feeling high on Prozac. Also felt anxious and put on more than 20kg.”
  • A male of unreported age “experienced severe depression, cognitive impairment and was acutely suicidal.”
  • A 16 year old girl was “cutting herself, throwing herself against the walls while an inpatient”. She “intentionally overdosed on Fluroxetine” and “developed severe levels of aggression and violence.”
  • A 14 year old boy experienced “suicidal ideation.”
  • A female of unreported age “experienced suicidal ideation”.
  • A 16 year old girl experienced “excessive bleeding, psychosis, high blood pressure, severe diarrhea, sweating, tremors, violent, aggressive and suicidal behavior, serotonin syndrome.”
  • A 14 year old male experienced “severely increased suicidal ideation in two days with high level of intent and plan to jump in front of train. Previously no suicidal ideation and settled spontaneously within four days of ceasing Fluoxetine”.
  • A female patient experienced a “sudden and marked increase in hostility and verbal abuse of others and describes intrusive suicidal ideation. Seems agitated and restless”.
  • A 32 year old woman experienced “audio hallucinations, bright and blurred vision, made everything sound louder, constipation, increased suicidal thoughts and increased anxiety”

http://www.perthnow.com.au/news/western-australia/prozac-is-now-a-defence-for-murder/story-e6frg13u-1226227796937

Note from CCHR International:  CCHR is the only organization to have decrypted the US FDAs Medwatch reports on adverse reactions to psychiatric drugs and compiled them in an easy to search database.    This database is provided here http://www.cchrint.org/psychdrugdangers/medwatch_psych_drug_adverse_reactions.php

CCHR has also compiled all international drug warnings and studies on psychiatric drugs here http://www.cchrint.org/psychdrugdangers/drug_warnings.php

 

« Return to news items


Share

Record Breaking $327 Million Verdict Upheld Against Manufacturer of Antipsychotic Risperdal—Request for New Trial Denied

Wednesday, December 21st, 2011

PR Newswire – December 21, 2011

(Click image for international warnings on antipsychotic drugs) The "dear doctor" letter, sent to more than 7,000 doctors across South Carolina, and the package insert were found to be misleading about the safety and effectiveness of the antipsychotic drug Risperdal.

The jury verdict in the case of State of South Carolina versus Ortho-McNeil-Janssen Pharmaceuticals and Johnson & Johnson, Inc. has been upheld and requests for a new trial denied, affirming groundbreaking $327 million in civil penalties against the manufacturers of the drug Risperdal.

Circuit Court Judge Roger Couch announced the rulings on December 20 through two written orders. One order denies the defendant’s motion for judgment notwithstanding the verdict or, in the alternative, for a new trial; the second order denies the defendant’s motion to alter or amend the judgment and/or for a new trial. John B. White, Jr. and Donald C. Coggins, Jr. of Harrison, White, Smith & Coggins, P.C., a Spartanburg-based law firm, along with John Simmons of the Simmons Law Firm, a Columbia-based law firm, and Bailey Perrin Bailey, a Texas based law firm represented South Carolina in the case.

“We are obviously very pleased with Judge Couch’s decision and his careful consideration of this matter,” stated John B. White, Jr. one of the attorneys representing the state in the case. “The verdict handed down by the jury is just and speaks the truth. The damages awarded further substantiated the level of deception Janssen used in business practices in our state. Once again, we have sent a clear message to drug companies that deceptive business practices will not be tolerated in South Carolina.”

On March 22, 2011 a jury in the Spartanburg Court of Common Pleas found that New Jersey-based Janssen willfully violated the South Carolina Unfair Trade Practices Act by engaging in unfair or deceptive acts or practices in the conduct of any trade or commerce in the “dear doctor” letter of November 10, 2003 and the drug label (package insert). This decision represents the first jury verdict that finds the defendant violated unfair trade practices since the inception of its pharmaceutical product. The “dear doctor” letter, sent to more than 7,000 doctors across South Carolina, and the package insert were found to be misleading about the safety and effectiveness of the antipsychotic drug Risperdal. Risperdal was introduced by Janssen in 1994 and by 2005, generated annual revenues in excess of $3.5 billion.

On June 3, 2011 civil penalties amounting to $327,073,700 were ordered by Circuit Court Judge Roger Couch based upon violations found with the drug labels and “dear doctor” letters. Regarding the drug label violations, the judge ruled that 509,499 package inserts were distributed with sample boxes, and levied $300 per violation for a total drug label awarded damages of $152,849,700. Regarding the “dear doctor” letter violations, the judge ruled that 7,184 letters were mailed and 36,372 were provided during sales calls, and levied $4000 per violation for a total “dear doctor” letter awarded damages of $174,224,000.

The combination of the drug label and letter damages of $327,073,700 amounts to the highest verdict brought against Janssen for the drug Risperdal.

http://www.marketwatch.com/story/record-breaking-327-million-verdict-upheld-in-janssen-case-and-request-for-new-trial-denied-2011-12-21

« Return to news items


Share

Can Prozac Cause Kids to Kill? A Canadian Judge Has Ruled it Can

Wednesday, December 7th, 2011

Note from CCHR:

(see videos at the bottom of this post from film maker Michael Moore and Fox National News reporter Douglas Kennedy)

It is well documented that psychiatric drugs, particularly antidepressants, can cause a host of violent side effects including mania, psychosis, aggression, violence and in the case of the antidepressant Effexor, homicidal ideation.   As far back as 1991, CCHR helped organize dozens of individuals and experts testifying before the US FDA that people with no prior history of violence (or suicide) became homicidal and suicidal under the influence of antidepressants (see CCHR’s exclusive footage of the 1991 hearings here).  It would take the FDA another 13 years to admit antidepressants could cause suicide and black box warnings were finally issued in 2004.  However, despite all the documented violence-inducing side effects of these drugs, the FDA has never issued black box warnings on antidepressants causing violence or homicide despite the fact that at least 11 recent school shootings were committed by kids documented to be on or in withdrawal from psychiatric drugs (see Fox News special report on school shootings here).   Therefore, the case cited below, where a Canadian judge ruled that a teenage boy murdered his friend due to being on the antidepressant Prozac, and the fact that the case will not be appealed, is a major turning point in exposing the violence inducing effects of antidepressant drugs.  

National Post
By Tom Blackwell
December 7, 2011

JB Reed/Bloomberg News

A Winnipeg judge’s ruling that a teenage boy murdered his friend because of the effects of Prozac will not be appealed, confirming an apparent North American first and reviving debate around the widespread prescription of anti-depressants to young people.

Justice Robert Heinrichs concluded the 15-year-old boy was under the influence of the medication when he thrust a nine-inch kitchen knife into the chest of Seth Ottenbreit, a close friend.

Although the killer pleaded guilty to second-degree murder, the judge cited the drug’s alleged side effects as a reason not to raise the case to adult court, and to mete out a sentence last month of just 10 months – on top of two years already spent in jail.

A spokeswoman for the Manitoba Justice Department said this week prosecutors have decided not to appeal the provincial-court decisions, which were earlier met with outrage from Mr. Ottenbreit’s family and friends.

Both the boy’s lawyer and the psychiatrist who testified on his behalf say it is the first time a criminal-court judge in North America has made such a finding.

Prozac is meant to curb the effects of depression, but Justice Heinrich concluded it set off a steady deterioration in the young murderer’s behaviour.

“He had become irritable, restless, agitated, aggressive and unclear in his thinking,” the judge said. “It was while in that state he overreacted in an impulsive, explosive and violent way. Now that his body and mind are free and clear of any effects of Prozac, he is simply not the same youth in behaviour or character.”

Yet the empirical underpinning of his conclusion, and the pros and cons of young people taking Prozac and other “selective serotonin reuptake inhibitor (SSRI)” anti-depressants, seem less clear-cut.

Justice Heinrichs relied largely on the expert testimony of Dr. Peter Breggin, a controversial American physician known for his outspoken opposition to the use of virtually any psychiatric drug. Some other experts say scientific evidence of a link between the latest anti-depressants and homicide is thin.

“I think it got pulled out of a hat, frankly,” said Dr. Umesh Jain, a child and adolescent psychiatrist at Toronto’s Centre for Addiction and Mental health. “You could construct a weak and biologically plausible effect, but you’d have to be pretty convincing in court.”

Studies have established such drugs can increase the risk of young patients having suicidal thoughts. Their tendency to lift inhibition could also release some hostility or violence lurking in a person’s character, said Dr. Jain. Small studies like one he co-authored in 1992 have also suggested that the drugs can trigger short-term mania, especially in bi-polar disorder patients.

There is little or no scientific evidence directly linking the anti-depressants and serious violence or homicide, though, he said.

Still, the official “product monograph” approved by Health Canada for Prozac says the drugs are not recommended for use on adolescents, and warns that agitation, hostility and aggression might ensue. Doctors are allowed to prescribe medications “off label” to patients even when the approval does not expressly permit it.

Specialists in Winnipeg responded to concerns voiced by the accused’s parents by actually increasing the dose, said Greg Brodsky, the teenager’s lawyer.

“On Prozac he was becoming more irrational and aggressive,” Mr. Brodsky said. “That should have been a warning. That warning wasn’t heeded.”

SSRI drugs have a contentious track record. They were hailed originally as a safe alternative to older anti-depressants, then clinical-trial results came to light in 2004 that suggested they increased the risk of children and adolescents having suicidal thoughts.

Other studies have indicated they are effective in patients with major depression, but little better than a placebo for mild to moderate cases.

The Winnipeg murderer had a history of smoking marijuana, had abused prescription drugs and “experimented” with cocaine, but was trying to break free of that background when a family doctor prescribed Prozac for depression in July, 2009.

On Sept. 20, the accused met with Mr. Ottenbreit and another friend at his house, after the two friends had earlier stormed into his home, allegedly damaging the floor. The killer and Mr. Ottenbreit shared a cigarette, before the accused pulled aside a sweater on the floor of his garage, revealing the knife. He picked it up, “got this weird look on his face,” then abruptly stabbed his friend, the other boy told police.

“They were in my house, they dented the floor, I had nothing else to do but to stab him,” he told police later.

Dr. Keith Hildahl, clinical head of Winnipeg’s Child and Adolescent Mental Health program, testified that the Prozac might have played a role, but concluded on balance that his behaviour that summer was largely a result of the tense relationship he had with his parents.

Dr. Breggin, who has testified in a number of U.S. cases where anti-depressants allegedly led to murder or other violence and reviewed the Winnipeg case, pointed the finger of blame at the medication.

“These drugs produce a stimulant or activation continuum,” he said in an interview. “That continuum includes aggression, hostility, loss of impulse control … all of which are a prescription for violence.”

Dr. Breggin’s long-standing criticism of psychiatric drugs and opposition to the view that psychiatric problems have biochemical roots have prompted some supporters to call him the “conscience” of the speciality, and some psychiatrists and patient advocates to condemn him as a harmful influence.

Read article here:  http://news.nationalpost.com/2011/12/07/prozac-defence-stands-in-manitoba-teens-murder-case/

See Michael Moore discuss the need for an investigation into psychiatric drugs causing violence:

See Fox National News on School Shootings and Psychiatric Drugs:

To read international warnings and studies on psychiatric drugs causing violence – visit CCHRInt’s Psychiatric Drug database and simply type in keywords such as violence, mania, psychosis, aggression in the red search box

« Return to news items


Share

SSRIs Render Unfriendly Skies—FOIA documents reveal what FAA failed to consider in allowing pilots on antidepressants to fly

Wednesday, July 14th, 2010

Scoop Independent News
By Evelyn Pringle
July 14, 2010

The SSRI antidepressant makers are desperate to find new customers, so they recently have been focusing on capturing groups for which the drugs were usually considered off limits. The latest marketing coup managed to open up sales to roughly 614,000 American pilots.

Under a new policy announced on April 5, 2010, pilots diagnosed with depression can seek permission from the Federal Aviation Administration to take one of four SSRIs, including Eli Lilly’s Prozac, Pfizer’s Zoloft, and Forest Laboratories’ Celexa and Lexapro.

“The FAA should reverse its ruling before it’s too late and hundreds of lives are lost when a pilot becomes impulsive, suicidal or violent–or just loses his sharpness–under the influence of antidepressant medication,” said SSRI expert, Dr Peter Breggin, in an April 19, 2010 Huffington Post commentary.

The Citizens Commission on Human Rights is also calling on the FAA to rethink allowing pilots to take SSRI in light of a new report issued last month by the National Transportation Safety Board, on a February 1, 2008 plane crash in North Carolina, by a crazy acting pilot on Zoloft, that killed all six persons on board

The report said the pilot failed to maintain control of the plane during instrument flying conditions and “deliberately descended below the minimum descent altitude.” The plane stalled and crashed while circling after an aborted landing.

“Review of the cockpit voice recorder (CVR) audio revealed that the pilot had displayed some non-professional behavior before initiating the approach,” the NTSB reported.

The CVR recorded the pilot singing: “Save my life I’m going down for the last time,” before beginning a commentary in which he told passengers: “If anybody back there believes in the good Lord, I believe now would be a good time to hit your knees.”

A review of medical records documented that “from December 4, 2006 through December 31, 2007, the pilot had filled 6 prescriptions for 30 tablets of 50 mg sertraline (Zoloft),” the report said.

The records indicated that he had been treated previously with two other antidepressant medications for “anxiety and depression” and a history of “impatience” and “compulsiveness,” the NTSB noted.

An investigation of another plane crash, resulting in two fatalities in Kingsport, Tennessee, in August 2003, found Zoloft in the blood and liver of a private flight instructor, according to an accident report by the NTSB.

In the policy statement published in the Federal Register, the FAA seems to justify the use of these drugs via the fully debunked “chemical imbalance in the brain” theory when writing: “All these medications are SSRIs, antidepressants that help restore the balance of serotonin, a naturally occurring chemical substance found in the brain.”

“Increasingly accepted and prevalently used, these four antidepressants may be used safely in appropriate cases with proper oversight and have fewer side effects than previous generations of antidepressants,” the FAA wrote, with no citation to any scientific paper to back up this assertion.

In fact, the current labels on SSRIs warn that “anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients treated for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.”

“Even when not severe, these reactions impair judgment and increase the likelihood of accidents and violence,” according to Dr Breggin.

CCHR has set up a great website with a one-of-a-kind search engine that allows the public and officials to access the database on side effects reported to the FDA on SSRIs, and every other psychiatric drug. The site also has a search engine to access all the International warnings and studies on psychiatric drugs which have been summarized so they are easy to understand, even to a lay person.

Input Only From the Choir

On April 6, 2010, Bob Fiddaman, author of the long-running popular website and blog, “Seroxat Sufferers,” sent a request to the FAA, under the Freedom of Information Act, seeking information on the change in policy.

In the Federal Register, the FAA claims it came to its decision after “careful consideration.” However, in the 58 pages of documents sent to Fiddaman on June 9, 2010 (and kindly shared with this author), there is no mention of consultations with any of the prominent SSRI experts who may have offered a contrary view. Like Peter Breggin for instance.

The FAA’s response to Fiddaman shows the agency has been discussing the policy change since at least 2008. In response to a request for “minutes of meetings where the change in the policy was on the agenda,” as well as a list of “members present and a declaration of interests of each of the members,” the FAA sent a copy of a July 18, 2008, Memorandum, with a summary from one consultants meeting. Three outside experts attended but there were no declarations of interests, or lack thereof, by anyone at the meeting.

The summary noted that the consultants “unanimously agreed that the concept of allowing certain airmen taking antidepressant medication was reasonable and safe.” But the “unanimous consensus” was that only Prozac and Zoloft “were appropriate medications due to the longevity of their use and overall safety.”

“They also felt that only these two should be considered initially, and no other medications considered at this time,” the summary reported.

In responding to the question of whether the new policy would apply to Air Traffic Controllers, the FAA said the “new policy does not presently apply to Air Traffic Control Specialist (ATCS) because the administrative details of the monitoring and follow-up of these employees are yet to be determined. The plan is that ATCSs will eventually be included in a program of this type.”

In response to a request for any information “given to FAA from outside parties that relate to the FAA’S recent change in policy regarding pilots on antidepressant medication,” the FAA sent copies of documents received from the Aerospace Medical Association, the Airline Pilots Association Aeromedical Office, the International Airline Pilots Association, and the United States Army.

“In developing the new policy, the FAA also utilized a variety of medical research literature available in the public domain,” the response said. “We used internet sites such as, but not limited to: The National Library of Medicine PubMed site and the FDA Medwatch.”

The documents Fiddaman received show consideration of a 2003 study of aviation accidents that found SSRIs in 61 pilot fatalities between 1990-2001, in which the psychological condition and/or the drug use was determined to be the cause, or a factor in 16 of the accidents, or 31%.

However, there was no mention of a later November 2006 study titled, “Pilot Medical History and Medications Found in Post Mortem Specimens for Aviation Accidents,” led by Dennis Canfield, from the FAA’s Civil Aerospace Medical Institute, in the “Aviation, Space, and Environmental Medicine” journal.

For this study, toxicological evaluations were performed on 4,143 pilots involved in fatal aviation accidents during the period between January 1, 1993, through December 31, 2003, to identify all pilots found positive for medications used to treat cardiovascular, psychological, or neurological conditions.

The evaluations found one-hundred dead pilots with SSRIs in their systems including forty with Prozac, twenty-six with Zoloft, twenty-one with Paxil, and thirteen with Celexa.

Less than a month after the new policy was announced, in “Aviation International News,” on May 1, 2010, Matt Thurber reported that in a review of 127 accidents in the NTSB database since 1991, containing the word “antidepressant,” only three were nonfatal.

“In 124 of those accidents, 211 people were killed,” Thurber said. “In accident after accident, antidepressants … were found in the tissues of dead pilots, and the pilots had falsified their medical certificate applications to show that they had never been treated for psychiatric problems.”

Read the rest of this article here:  http://www.scoop.co.nz/stories/HL1007/S00116.htm

Read FOIA documents here: http://fiddaman.blogspot.com/p/faa-respond-to-freedom-of-information.html

« Return to news items


Share

The FAA will Allow Antidepressant Popping Pilots and their Lethal Side Effects in an Unfriendly Sky

Monday, April 5th, 2010

PR-inside.com
April 5, 2010

Ever wonder, which government agency would be most likely to put a person in harms way. If you join the military then you volunteer to be placed in the line of fire if under enemy attack. The antidepressant use can also kill you on the base just like it did at Ft. Hood several months ago. The IRS will use fear instead of mortality, but they can certainly incarcerate you which could be a slow death. The FDA has been approving psychotropic drugs, heart medications, birth control pills et al, with horrendous track records and mortal consequences since its inception. Some of those drugs have been taken off the market, but most like antidepressants are still available even though it is widely known they depress patients. Now we have the latest US government agency the FAA, which will now allow pilots to medicate and fly.

Some of the side effects of these now allowable medications (Prozac, Zoloft, Celexa, Lexapro) are suicide, mania, agitation, dizziness, fatigue, insomnia, tremors, muscle aches, diarrhea, fast heartbeat, fever chills, fainting, bizarre behavior, aggressiveness, joint or wrist aches and pain, ringing in the ears, confusion, decreased concentration, decreased coordination, exaggerated feeling of well being, irritability, hostility, memory loss, vomiting, mood changes, unusual weakness, vision changes, hallucinations, and worsening of depression. Do you feel safe to fly in a tin can at 35,000 feet when the pilot may have one or more of these side effects? It seems clear the FAA is looking at only one head in the head count. Based on these side effects you could have a maniac flying the plane! You should get thrown off the plane for bizarre behavior, but today you get to be the captain.

Read entire article:  http://www.pr-inside.com/the-faa-will-allow-antidepressant-popping-r1813445.htm

Click here for a related video:  http://www.newsy.com/videos/pilots-on-antidepressants-permitted-to-fly

« Return to news items


Share

Illinois Department of Public Health: 5 things to know about psychotropics (including the right to informed consent)

Tuesday, October 27th, 2009

Illinois Dept. of Public Health
Chicago Tribune
October 27, 2009

Your rights: Nursing homes cannot give a psychotropic drug without a doctor’s order, informed consent and an adequate diagnosis, according to federal and state regulations. Drugs cannot be administered simply because a resident is disruptive or restless. Rules and guidelines dictate that staff must first try to calm patients; root causes of agitation, such as an infection, must be ruled out. When drugs are given, facilities must check for side effects and reduce dosages when possible.

The consent: Consent forms must be signed by patients or someone with power of attorney. In general, consents must say what drug will be given, how much and how often. If a doctor wants to add a drug, the consent must be re-signed. The patient must be fully informed of risks.

Read entire article: http://www.chicagotribune.com/health/chi-nursing-home-tips-27-oct27,0,7460931.story

« Return to news items


Share